These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 972914)

  • 1. The complement system: a progress report.
    Prahl JW
    Prog Clin Biol Res; 1976; 5():43-67. PubMed ID: 972914
    [No Abstract]   [Full Text] [Related]  

  • 2. Biochemistry and biological activity of the complement system.
    Surján M
    Ann Immunol Hung; 1973; 17():101-15. PubMed ID: 4618445
    [No Abstract]   [Full Text] [Related]  

  • 3. The complement system of man. I.
    Ruddy S; Gigli I; Austen KF
    N Engl J Med; 1972 Sep; 287(10):489-95. PubMed ID: 4114930
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunobiology and clinical importance of the complement system of man.
    Spitzer RE
    Adv Pediatr; 1977; 24():43-101. PubMed ID: 341668
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyanate as an inactivator of complement proteins.
    Schultz DR; Arnold PI
    J Immunol; 1975 Dec; 115(6):1558-65. PubMed ID: 1184967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephritic factor, C3 splitting activity, C3 and factor B breakdown products in glomerular diseases.
    De Vecchi A; Montagnino G; Scalia P; Tarantino A
    Ric Clin Lab; 1980; 10(1):93-7. PubMed ID: 6781054
    [No Abstract]   [Full Text] [Related]  

  • 7. Complement components and lymphoid cell surfaces.
    McConnell I
    Proc R Soc Med; 1976 Sep; 69(9):657-61. PubMed ID: 981263
    [No Abstract]   [Full Text] [Related]  

  • 8. The C3 nephritic factor (C3NeF) and the heat labile complement inactivator (HLCI) in chronic hypocomplementemic mesangioproliferative glomerulonephritis.
    Berthoux FC; Carpenter CB; Traeger J; Merrill JP
    Adv Nephrol Necker Hosp; 1974; 4():91-108. PubMed ID: 4220002
    [No Abstract]   [Full Text] [Related]  

  • 9. Activation, activities and pharmacologically active products of complement.
    Vogt W
    Pharmacol Rev; 1974 Jun; 26(2):125-69. PubMed ID: 4609350
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of C3 receptors on lymphoid cells with different complement sources.
    Dierich MP; Pellegrino MA; Ferrone S; Reisfeld RA
    J Immunol; 1974 May; 112(5):1766-73. PubMed ID: 4522461
    [No Abstract]   [Full Text] [Related]  

  • 11. Relationships among the complement, kinin, coagulation and fibrinolytic systems in the inflammatory reaction.
    Sundsmo JS; Fair DS
    Clin Physiol Biochem; 1983; 1(2-5):225-84. PubMed ID: 6241121
    [No Abstract]   [Full Text] [Related]  

  • 12. [The third component of complement and complement receptors (author's transl)].
    Okuda T; Tachibana T
    Tanpakushitsu Kakusan Koso; 1974 Sep; 19(9):657-67. PubMed ID: 4215099
    [No Abstract]   [Full Text] [Related]  

  • 13. Activation of complement in human nephritis.
    Lambert PH; Perrin LH; Mahieu P; Nydegger UE; Miescher PA
    Adv Nephrol Necker Hosp; 1974; 4():79-90. PubMed ID: 4220001
    [No Abstract]   [Full Text] [Related]  

  • 14. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
    Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
    Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer research center hotline: complement depletion: use of human C3/cobra venom factor (CVF) chimeric proteins as therapeutic agents.
    Fritzinger DC
    Hawaii Med J; 2005 May; 64(5):133-4, 137. PubMed ID: 15989147
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
    Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
    Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and identification of the third component of complement of Japanese quails.
    Kai C; Yoshikawa Y; Yamanouchi K; Okada H
    J Immunol; 1983 Jun; 130(6):2814-20. PubMed ID: 6343485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The possible role of membrane complement regulators in vasculitis.
    Daha MR
    Behring Inst Mitt; 1993 Aug; (92):184-90. PubMed ID: 7504449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro effect of Iopamidol on coagulation, fibrinolysis and complement system (author's transl)].
    Schulze B; Beyer HK
    Arzneimittelforschung; 1981; 31(7):1067-9. PubMed ID: 7196754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Activity of total complement and concentration of its components C1q, C3, C4 and C1-inactivator in cancer].
    Matoses Cuquerella S; O'Connor Miquel C; Lluch Hernández AM; García-Conde Bru J
    Med Clin (Barc); 1988 Dec; 91(20):769-74. PubMed ID: 3266280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.